Physician profile
John J Osowski
NPI 1205085719
$1,928.10
in general payments reported to CMS, 2019-2025
21 companies · $102 in 2025
The $102 reported for 2025 was more than what a typical Hospitalist provider received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $121 · 2020: $126 · 2021: $274 · 2022: $353 · 2023: $308 · 2024: $644 · 2025: $102.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $950 · Education: $104.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $949.88 |
| Education | $103.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $285.52 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $184.51 | 2019-2024 | |
| Alexion Pharmaceuticals, INC. | $164.41 | 2021-2025 | Ultomiris, Soliris |
| Astellas Pharma US INC | $159.01 | 2024 | Cresemba |
| Astrazeneca Pharmaceuticals LP | $149.76 | 2020-2023 | Farxiga |
| Mallinckrodt Hospital Products INC. | $148.96 | 2023-2025 | Terlivaz |
| E.R. Squibb & Sons, L.L.C. | $144.11 | 2021-2024 | Camzyos, Eliquis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $130.80 | 2019-2025 | Xifaxan |
| Pfizer INC. | $114.12 | 2020-2024 | |
| Ferring Pharmaceuticals INC. | $90.27 | 2023-2024 | Rebyota |
| Csl Behring | $67.04 | 2020-2022 | |
| Alcresta Therapeutics, INC. | $53.19 | 2019-2024 | Relizorb |
| Genzyme Corporation | $47.73 | 2021-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $35.43 | 2022-2023 | Lifevest |
| Abbvie INC. | $30.97 | 2024 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $24.19 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.52 | 2021 | |
| Eisai INC. | $22.90 | 2024 | |
| Merck Sharp & Dohme LLC | $18.34 | 2019 | |
| Janssen Biotech, INC. | $17.17 | 2022 | |
| Gilead Sciences, INC. | $16.15 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Osowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.